

receptors or complexing agents, chelators, encapsulating vehicles short- or long-chain aliphatic or aromatic hydrocarbons, [including those containing] aldehydes, ketones, alcohols, esters, amides, amines, nitriles, and azides [, or other hydrophilic or hydrophobic moieties].

5 (Amended). The radiosensitizer agent of Claim 1 wherein said radiosensitizer agent also is an imaging contrast agent.

6 (Amended). The radiosensitizer agent of Claim 5 wherein said radiosensitizer acts as an imaging contrast agent for computed axial tomography [CAT scan].

7 (Amended). The radiosensitizer agent of Claim 5 wherein said radiosensitizer acts as an imaging contrast agent for X-ray imaging.

8 (Amended). The radiosensitizer agent of Claim 1 wherein said halogenated xanthene includes at least one halogen [has a large content of an element] selected from the group [comprising] consisting of iodine and bromine.

9 (Amended). The radiosensitizer agent of Claim 1 wherein said radiosensitizer agent is a halogenated xanthene selected from the group [comprising] consisting of Phloxine B, Erythrosin B and Eosin Y [and their derivatives].

10 (Amended). The radiosensitizer agent of Claim 1 wherein said halogenated xanthene is activated using x-rays having an energy greater than 30 keV.

Cancel Claim 11.

12 (Amended). A radiosensitizer agent for treatment of [diseased tissue] cancer and tumors using radiosensitization or ionizing radiation, said radiosensitizer agent comprising a halogenated xanthene, wherein said radiosensitizer agent substantially concentrates [exhibits a preference for concentration] in [biologically sensitive structures in tissue] said cancer or tumors.

B2  
13 (Amended). The radiosensitizer agent of Claim 12 wherein said radiosensitizer agent substantially concentrates [exhibits a preference for concentration] in cellular membranes of said cancer or tumors.

Sub C67  
~~14 (Amended). The radiosensitizer agent of Claim 12 wherein at least one biological targeting moiety is attached to said radiosensitizer agent to enhance targeting of said radiosensitizer agent to [biologically targets said] biologically sensitive structures of said cancer or tumors.~~

~~15 (Amended). The radiosensitizer agent of Claim 12 wherein at least one chemical targeting moiety is attached to said radiosensitizer agent to enhance targeting of said radiosensitizer agent to [chemically targets said] biologically sensitive structures of said cancer or tumors.~~

16 (Amended). The radiosensitizer agent of Claim 14 wherein said targeting is by [chemical] partitioning of the radiosensitizer agent at a position proximate to [at, near] or into [the] biologically sensitive structures of said cancer or tumors.

Cancel Claim 17.

Sub C7>

18 (Amended). The radiosensitizer agent of Claim [17] 14 wherein said radiosensitizer agent is delivered by encapsulation of said radiosensitizer agent in a delivery vehicle.

B3

19 (Amended). The radiosensitizer agent of Claim 18 wherein said [agent] halogenated xanthene is Rose Bengal [or its derivatives].

20 (Amended). The radiosensitizer agent of Claim [19] 18 wherein said delivery vehicle is selected from the group consisting of [comprising a] micelles, [a] nanoparticles and [a] liposomes.

Cancel Claims 21-22.

B4

23 (Amended). The radiosensitizer agent of Claim 15 wherein said targeting is by [chemical] partitioning of the radiosensitizer agent at a position proximate to [at, near] or into [the] biologically sensitive structures of said cancer or tumors.

Cancel Claim 24.

25 (Amended). The radiosensitizer agent of Claim [24] 15 wherein said radiosensitizer agent is delivered by encapsulation of said radiosensitizer agent in a delivery vehicle.

B5

26 (Amended). The radiosensitizer agent of Claim 25 wherein said [agent] halogenated xanthene is Rose Bengal.

4B-5  
( ) ( )  
27 (Amended). The radiosensitizer agent of Claim 25 wherein said delivery vehicle is selected from the group [comprising] consisting of [a] micelles, [a] nanoparticles and [a] liposomes.

~~Cancel Claims 28-30~~

Sub 87  
4B-6  
~~51 (Amended). The radiosensitizer agent of Claim 1 wherein said ionizing radiation is approximately greater than or equal to 1 keV and less than or equal to approximately 1000 MeV.~~

~~52 (Amended). The radiosensitizer agent of Claim 12 wherein said ionizing radiation is approximately greater than or equal to 1 keV and less than or equal to approximately 1000 MeV.~~

~~Please add the following new claims:~~

-- 54. The radiosensitizer agent of Claim 12 wherein said halogenated xanthene is a functional derivative formed by attachment of at least one moiety at positions R<sup>1</sup> or R<sup>2</sup>. --

4B-Sub 89  
7  
~~-- 55. The radiosensitizer agent of Claim 1 wherein said halogenated xanthene includes as a functional derivative a targeting moiety selected from the group consisting of hydrophilic and hydrophobic moieties. --~~

-- 56. The radiosensitizer agent of Claim 1 wherein said ionizing radiation comprises x-rays. --

-- 57. The radiosensitizer agent of Claim 56 wherein said x-rays have an energy between 30 kiloelectron volts and 1000 megaelectron volts. --

-- 58. The radiosensitizer agent of Claim 12 wherein said halogenated xanthene is Rose Bengal.--

4B7 -- 59. The radiosensitizer agent of Claim 12 wherein said radiosensitizer agent substantially concentrates in biologically sensitive structures of said cancer or tumors. --

#### REMARKS

Applicants are amending the specification to reflect the earlier application to which Applicants wish to claim priority. Applicants are also amending the Abstract of the Disclosure, as suggested by the Examiner. It is believed that no new matter is being added. Accordingly, it is requested that this amendment be entered and allowed.

Applicants will submit formal drawings when the application has been allowed to overcome the objections to informalities in the drawings as filed.

In the Office Action, the Examiner rejects Claims 2-30 and 52 under 35 USC §112 as being indefinite. In response, Applicants have amended the claims to address each of the Examiner's objections to informalities in the claims. Applicants believe that most of these amendments need no further explanation. Applicants are providing the following comments in response to a few specific objections of the Examiner: